40results about How to "Good stability in vitro" patented technology

The invention provides PEGylated benzyltriazolyl pyridazinone compounds of which the molecular formula is Fmppn. The structure of the pyridazinone compounds is disclosed as Formula (1), wherein n is a whole number ranging from 1 to 8; and F is 19F or 18F. The compounds provided by the invention have the characteristics of simple preparation process, low use cost, high radiochemical yield, high radiochemical purity, high stability, favorable biological properties, high target to non-target ratio, high myocardial uptake ratio and the like, and can be applied to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine as a novel fluorine-18 labeled myocardial perfusion developer.

The invention discloses an application of a mutant single-chain human blood coagulation factor VIII in preparation of a fusion protein of the human blood coagulation factor VIII; the fusion protein sequentially comprises a B-structural domain partially deleted mutant single-chain human coagulation factor VIII, a flexible peptide joint, at least one human chorionic gonadotropin beta subunit carboxyl terminal peptide rigid unit and a half-life prolonging part from an N terminal to a C terminal, and is used for preventing or treating hemorrhagic diseases.

The invention relates to application of a liposome to preparation of a drug for treating chronic viral hepatitis B, wherein the liposome is prepared from a substance containing phospholipid and cholesterol. The invention further relates to application of the liposome to preparation of drugs for promoting serology conversion, namely hepatitis B E antibody positive conversion and hepatitis B E antigen negative conversion, of chronic viral hepatitis B patients, for reducing the titer of hepatitis B virus in peripheral blood serum of chronic viral hepatitis B patients, for reducing the concentration of glutamic-pyruvic transaminase in peripheral blood serum of chronic viral hepatitis B patients, and for maintaining the stability of a T cell receptor repertoire of chronic viral hepatitis B patients.

This application relates to the field of biomedical technology, in particular to miRNA markers related to active tuberculosis and their applications, wherein the miRNA markers related to active tuberculosis include miR-451a, miR-25-3p, miR-425 ‑5p, miR‑1260b, miR‑1273g‑3p, miR‑30e‑5p, miR‑140‑3p, let‑7a‑5p, miR‑1290, miR‑491‑5p, miR‑3615, miR‑15a‑5p One or more of miR-21-3p, miR-424-5p, miR-1268a, miR-1301-3p, miR-345-5p, miR-572, miR-375, miR-151a-5p.

The invention discloses a technetium-labeled estradiol derivative and a reference compound thereof, and a preparation method, an application and an intermediate thereof. The technetium-labeled estradiol derivative is shown in the formula VII, wherein A is a group -(CH2CH2)x- or -(CH2CH2O)m(CH2CH2)n-; and x, m and n are integral numbers, x is 1-6, m is 1-3, and n is 1-3. The technetium-labeled estradiol derivative has a moderate lipid / water partition coefficient, and can be used for preparing imaging drugs for diagnosing breast cancer. The in-vitro experiment indicates that the technetium-labeled estradiol derivative has favorable affinity with an estrogen receptor, and has favorable in-vitro stability and moderate metabolism speed in phosphate buffer solution (PBS), 1mM histidine solution, 1mM cysteine solution, 1mM diethylene triamine pentacetic acid (DTPA) solution and newborn calf serum. The technetium-labeled estradiol derivative is hopeful to become a radioactive drug which has good targeting property, is suitable for continuing deep research in organisms and is used for diagnostic imaging.

The invention belongs to the technical field of biology and provides a 125I-labeled Caerin polypeptide and an application thereof to preparation of a drug for treating tumors and particularly benign and malignant tumors relevant to HPV infection. The 125I-labeled Caerin polypeptide provided by the invention is prepared by using an optimized direct labeling method, and the preparation method is simple and convenient to operate, high in labeling rate, short in reaction time and good in in-vivo and in-vitro stability. The 125I-labeled polypeptide prepared after a Caerin polypeptide is 125I-labeled has a remarkable effect on inhibiting tumor cells and is capable of remarkably improving the treatment effect of the Caerin polypeptide, reducing the use dosage of the Caerin polypeptide and reducing the preparation cost and chemical toxicity of the drug for treating the tumors and particularly tumors relevant to HPV infection, so that the treatment cost of the tumors is reduced, and the medication safety of the tumors is improved.